Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Compugen Establishes Operations in California for Development of mAb Drug Candidates

Published: Thursday, September 27, 2012
Last Updated: Thursday, September 27, 2012
Bookmark and Share
Dr. Mary Haak-Frendscho and Dr. John J. Hunter to lead new operations.

Compugen Ltd. has announced the establishment of operations in South San Francisco, California for the development of oncology and immunology monoclonal antibody (mAb) drug candidates against Compugen-discovered targets.

The mission for Compugen Inc., a wholly owned subsidiary of Compugen Ltd., is to translate the growing portfolio of novel mAb targets being discovered and validated by the parent company into promising mAb drug candidates for licensing and partnering.

Compugen Ltd. has also announced the appointment, effective April 1, of Mary Haak-Frendscho, Ph.D., as Executive Chairperson of Compugen Inc., and John J. Hunter, Ph.D., as Compugen Inc.'s Vice President of Antibody R&D and Site Head.

The new South San Francisco Compugen Inc. operations will be located in recently secured purpose-built facilities with relevant laboratory equipment.

By locating its mAb operation in the birthplace of biotech, the Company gains access to some of the best biologics talent in the industry and supportive infrastructure.

Furthermore, with these new capabilities, Compugen anticipates that it will significantly increase the number of mAb product candidates developed against novel Compugen-discovered targets by performing key activities more effectively and efficiently in-house compared with solely using third parties as previously intended.

Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., said, "We are extremely pleased to be establishing these new operations under the direction and expertise of Dr. Haak-Frendscho and Dr. Hunter, two prominent figures in the mAb biotechnology industry. We are at a pivotal moment where Compugen's unique Monoclonal Antibody Targets Discovery Platform is delivering high quality, novel mAb targets that enable the development of new drug candidates to address unmet medical needs. We enthusiastically look forward to leveraging the commercial potential of these pioneering and industry leading predictive discovery capabilities by licensing out - at significantly greater values – the differentiated mAb product candidates against these novel targets, rather than the targets."

Dr. Mary Haak-Frendscho added, "Dr. Hunter and I are delighted to establish and lead Compugen's subsidiary for the development of therapeutic mAb candidates. Given Compugen's cutting edge science and growing portfolio of exciting mAb targets, we look forward to working closely with Compugen's scientists and management team in Israel to ensure the development of differentiated therapeutic mAb products."

In her role as Executive Chairperson of Compugen Inc., Dr. Haak-Frendscho will be responsible for overseeing the establishment and development of Compugen Inc.'s mAb operations.

Dr. Haak-Frendscho has more than 20 years of industry experience, most recently as founding President and Chief Scientific Officer at Takeda San Francisco, Inc., the antibody IND engine for Takeda Pharmaceuticals. Prior to that, she held senior scientific and management positions at Genentech, Abgenix and XOMA.

John J. Hunter, Ph.D., brings to Compugen Inc. over 15 years of scientific expertise in mAb research, genomics and translational medicine.

As Vice President Antibody Research and Development and Compugen Inc. Site Head, he will lead the therapeutic mAb generation and preclinical development of mAb therapeutics against Compugen-discovered targets.

Prior to joining Compugen, Dr. Hunter served as a Senior Director at XOMA, managing strategic and functional activities related to building a robust preclinical mAb pipeline. He began his industry career at Millenium Pharmaceuticals, where he specialized in oncology therapeutics research.

Today's announcement follows the Company's December 2011 announcement that it intends to significantly broaden and accelerate its mAb activities, which together with therapeutic proteins, represent the focus areas for the Company in the fields of oncology and immunology.

At that time, and in partial support of its mAb operations expansion, the Company also announced an $8 million research funding agreement signed with Baize Investments (Israel) Ltd., a private corporation investing in innovative medical technologies.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Compugen Discloses New Results Supporting CGEN-15052
Data presented at the Inaugural International Cancer Immunotherapy Conference in New York City.
Thursday, September 17, 2015
Compugen Obtains Rights to Use Biological Systems and Materials
Additional capabilities anticipated to enhance research and development of Compugen’s immuno-oncology programs.
Wednesday, April 15, 2015
Compugen Announces Planned Relocation of Headquarters to Larger Facilities
New facilities double available space for corporate offices and research and discovery in Israel.
Wednesday, March 25, 2015
Compugen Expands and Strengthens Business Development Team
Felix Karim, PhD, joins Company as Vice President Corporate & Business Development.
Tuesday, March 10, 2015
Compugen Discloses Initial Experimental Results for Predicted ADC Targets
Pipeline program for oncology to be further expanded and diversified with addition of ADC therapeutic programs to ongoing immuno-oncology programs.
Tuesday, January 06, 2015
Compugen Announces Presentations of Results for CGEN-15001
Data indicating novel mechanism of action for CGEN-15001 in maintaining long-term therapeutic effect presented at International Conference on Immune Tolerance in Amsterdam.
Wednesday, October 01, 2014
Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins
Incorporation of algorithms modeling additional biological phenomena leads to predictive discovery of four potential immunomodulatory targets.
Tuesday, July 15, 2014
Compugen Announces Addition of Prof. Drew Pardoll to its SAB
Prof. Pardoll is a world leader in immuno-oncology research and in the development of novel cancer therapeutics.
Wednesday, January 22, 2014
Compugen Discloses Discovery of Five Potential Cancer Targets for ADC Therapy
ADC target discovery is company’s second focused discovery program utilizing its in silico predictive discovery infrastructure.
Thursday, December 12, 2013
Compugen Drug Candidate Demonstrates High Effectiveness in Type I Diabetes Animal Model
Short-term administration of CGEN-15001 shown to provide long-term prevention of disease development.
Friday, October 11, 2013
Compugen Target for Cancer Immunotherapy Shown to Affect Multiple Immune Cell Types
CGEN-15049 immune checkpoint protein expressed on wide variety of cancers.
Thursday, September 26, 2013
Compugen Establishes SAB to Guide Pipeline Program Development
Key opinion leaders to advise Company on research and development involving therapeutic product candidates in the fields of immunology and oncology.
Tuesday, August 27, 2013
Compugen Announces Collaboration and License Agreement with Bayer
Compugen to hold 2nd Quarter Conference Call August 7, 2013.
Tuesday, August 06, 2013
Compugen Reports First Quarter 2013 Financial Results
CEO to update Company status in quarterly conference call.
Monday, April 29, 2013
Compugen Discloses Focused Target Discovery Program for ADC Cancer Therapy
Initial discoveries from new program anticipated before year-end.
Tuesday, April 09, 2013
Scientific News
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Four Gut Bacteria Decrease Asthma Risk in Infants
New research by scientists at UBC and BC Children’s Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Antibiotic Overuse Might be Why so Many People Have Allergies
The Centers for Disease Control and Prevention estimates that drug resistant bacteria cause 23,000 deaths and two million illnesses each year.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos